Apnimed Named 2024 Best Places to Work Company by the Boston Business Journal
May 07, 2024 08:00 ET
|
Apnimed, Inc.
Apnimed Named 2024 Best Places to Work Company by the Boston Business Journal
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
May 06, 2024 07:15 ET
|
SAB Biotherapeutics, Inc.
MIAMI, May 06, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human...
BetterLife Announces Intent to Complete Private Placement of Units
May 03, 2024 18:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, May 03, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
Alvotech tekur þátt í heilbrigðisráðstefnu BofA Securities í Bandaríkjunum
May 02, 2024 07:15 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að félagið taki þátt í árlegri heilbrigðisráðstefnu BofA Securities, sem haldin verður dagana 14. – 15. maí í Las Vegas, Nevadafylki Bandaríkjanna. Fulltrúar úr...
Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
May 02, 2024 07:15 ET
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that members of management would be...
BetterLife Advances BETR-001 IND-enabling Studies
May 01, 2024 08:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, May 01, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
April 19, 2024 06:10 ET
|
Alvotech
Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar to...
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
April 16, 2024 17:30 ET
|
Alvotech
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the...
BetterLife To Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
April 11, 2024 08:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
SAB Biotherapeutics to Present at INNODIA Annual Meeting
April 08, 2024 07:15 ET
|
SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. today announced their Chief Medical Officer will share an overview of the SAB-142 clinical development plan at INNODIA.